🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the pathogen, according to health experts.

An International Challenge

Gonorrhoea infections are increasing globally, with figures suggesting over 82 million infections each year. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely development in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices currently available.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Secure Clearance

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists believe that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a unique collaborative effort for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization represents a significant shift in the treatment of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Results and Worldwide Availability

According to findings released by a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This puts it on an equal footing with the typical regimen, which uses two antibiotics. The research enrolled hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in numerous regions with limited resources.

Medical professionals directly involved have voiced hope. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for managing the epidemic. This is considered vital to reduce the burden of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.